Economic evaluation of human papillomavirus vaccination in the Global South: a systematic review
- PDF / 704,757 Bytes
- 15 Pages / 595.276 x 790.866 pts Page_size
- 17 Downloads / 212 Views
(0123456789().,-volV)(0123456789(). ,- volV)
REVIEW
Economic evaluation of human papillomavirus vaccination in the Global South: a systematic review Saba Abidi1 • Satyanarayana Labani2 • Aastha Singh1 • Smita Asthana2 • Puneeta Ajmera1 Received: 30 January 2020 / Revised: 30 June 2020 / Accepted: 8 July 2020 Swiss School of Public Health (SSPH+) 2020
Abstract Objectives Many reviews have been conducted on the economic evaluation of the HPV vaccine in global north countries. But there is a dearth of such reviews in the Global South countries. Hence, this systematic review aims to summarize studies done in these countries. Methods Four databases PubMed, Embase, Cochrane Library, and Google Scholar from 2009 to 2019 were searched for economic evaluations on HPV vaccination in the Global South countries. PRISMA guidelines were followed to include full-text articles. 40 original articles were shortlisted for full-text review. Results Studies had varied models, assumptions, and results according to different scenarios. Most studies concluded HPV vaccination to be cost-effective under varied scenarios and vaccine cost was the most influential parameter affecting the sensitivity analyses, consequently incremental cost-effectiveness ratio. A wide range in the cost-effectiveness ratio was observed in the included studies due to different study settings, populations, and inconsistencies in modeling practices (variations in methodological approaches). Conclusions This review suggests the introduction of HPV vaccination alone or in combination with screening according to different countries. The price of the vaccine should be economical and funds for the vaccine should be provided by public sector firms. Keywords Cost-effectiveness Economic evaluation Global South HPV vaccination ICER
Introduction This article is part of the special issue ‘‘Market-driven forces and Public Health’’.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00038-020-01431-1) contains supplementary material, which is available to authorized users. & Saba Abidi [email protected] Satyanarayana Labani [email protected]
Cervical cancer is the fourth most frequent cancer in women with an estimated 570,000 new cases in 2018 representing 6.6% of all female cancers. Approximately 90% of deaths from cervical cancer occurred in low- and middle-income countries (Vu et al. 2018). Most of the 1
Delhi Pharmaceutical Sciences and Research University, New Delhi, India
2
Indian Council of Medical Research – National Institute of Cancer Prevention and Research, Noida, Uttar Pradesh, India
Aastha Singh [email protected] Smita Asthana [email protected] Puneeta Ajmera [email protected]
123
S. Abidi et al.
countries in the Global South belong to low or middleincome countries and have got a high incidence of Cervical cancer. According to GLOBOCAN 2018, the top five countries of the high incidence of cervical cancer are part of the Global South (namely Swaziland, Malawi, Zambia
Data Loading...
